Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

4.62USD
20 Aug 2018
Change (% chg)

-- (--)
Prev Close
$4.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,850
52-wk High
$7.24
52-wk Low
$3.12

Latest Key Developments (Source: Significant Developments)

Chromadex Corporation Q4 Loss Per Share $0.17
Thursday, 8 Mar 2018 04:01pm EST 

March 8 (Reuters) - Chromadex Corp ::ORATION REPORTS 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.17.Q4 SALES ROSE 69 PERCENT TO $7.5 MILLION.Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION.QTRLY ADJUSTED EBITDA PER SHARE WAS A LOSS OF $0.10.  Full Article

Chromadex Chairman Stephen Allen Will Retire From The Board
Friday, 16 Feb 2018 04:30pm EST 

Feb 16 (Reuters) - Chromadex Corp ::CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS.CHROMADEX CORP - ‍ ALLEN WILL NOT STAND FOR RE-ELECTION AS A DIRECTOR AT CHROMADEX'S 2018 ANNUAL MEETING IN JUNE​.  Full Article

ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln
Monday, 12 Feb 2018 06:30am EST 

Feb 12 (Reuters) - ChromaDex Corp ::ORATION REPORTS PRELIMINARY 2017 RESULTS.SEES Q4 2017 REVENUE ABOUT $7.5 MILLION.SEES FY 2017 REVENUE ABOUT $21.2 MILLION.AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION.‍FOR FULL YEAR 2017, OPERATING LOSS FROM CONTINUING OPERATIONS IS EXPECTED TO BE IN A RANGE OF $16 MILLION TO $17 MILLION​.  Full Article

Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders
Thursday, 14 Dec 2017 05:06pm EST 

Dec 14 (Reuters) - Chromadex Corp ::CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

ChromaDex Q3 loss per share $0.07 from continuing operations
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - ChromaDex Corp ::ChromaDex reports third quarter 2017 financial results.Q3 loss per share $0.07 from continuing operations.Q3 sales rose 55 percent to $6.1 million.  Full Article

Chromadex announces $23 mln private placement of common stock
Monday, 6 Nov 2017 06:30am EST 

Nov 6 (Reuters) - Chromadex Corp :Chromadex announces $23 million private placement of common stock.Chromadex Corp - in connection with investment, co agreed to sell 5.6 million shares of common stock at a per share price of $4.10​.Chromadex Corp - ‍net proceeds of investment expected to provide co added resources to accelerate plans related to nad+ in general, tru niagen in particular​.  Full Article

Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln
Tuesday, 31 Oct 2017 04:59pm EDT 

Oct 31 (Reuters) - Chromadex Corp :Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing.  Full Article

Chromadex appoints Kevin Farr as new CFO
Monday, 9 Oct 2017 06:30am EDT 

Oct 9 (Reuters) - Chromadex Corp :Chromadex appoints Kevin Farr as new CFO.Chromadex Corp says ‍Chromadex expects that Thomas Varvaro will transition from Chromadex over coming months to pursue other opportunities​.  Full Article

Chromadex announces top-line results of its second human clinical trial
Tuesday, 26 Sep 2017 06:30am EDT 

Sept 26 (Reuters) - Chromadex Corp ::Chromadex announces top-line results of its second human clinical trial.Chromadex Corp - ‍results from trial demonstrated that NR produced statistically significant increases in blood NAD+ compared to placebo​.Chromadex Corp - ‍initial results of Niagen nicotinamide riboside chloride (NR) confirmed NR significantly raises co-enzyme NAD+ over 8-weeks.Chromadex Corp - ‍study establishes effective dose range and validates safety for Niagen nicotinamide riboside chloride in 140 humans over an 8-week period​.Chromadex Corp - ‍study confirms not only efficacy in raising NAD+, but also definitively documents safety of daily use of NR​.  Full Article

ChromaDex Partners with Watsons, for TRU NIAGEN retail launch
Thursday, 7 Sep 2017 06:30am EDT 

Sept 7 (Reuters) - Chromadex Corp :ChromaDex Corp - new partnership with Hong Kong based retailer, A.S. Watson, for launch of U.S. Made TRU NIAGEN) dietary supplement in Asia.  Full Article

BRIEF-Chromadex Q1 Loss Per Share $0.15

* Q1 SALES ROSE 95 PERCENT TO $6.6 MILLION Source text for Eikon: Further company coverage: